Search tips
Search criteria 


Logo of oncotargetLink to Publisher's site
Oncotarget. 2017 January 10; 8(2): 2466–2476.
Published online 2016 November 29. doi:  10.18632/oncotarget.13690
PMCID: PMC5356816

FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma


Cancer stem cells are proposed to be responsible for resistance to chemotherapeutic agents, including doxorubicin. As phenylbutyrate enhances cancer stem cell properties, we analyzed surviving lymphoma cells after treatment with doxorubicin and phenylbutyrate. Human B-cell lymphoma cell lines, including Toledo, BJAB, Daudi, and Raji were incubated with IC90 concentrations of doxorubicin (300 nM) or phenylbutyrate (8 mM). After 48 h, live cells were sorted and analyzed for their resistance to treatment by examining gene expression profiles using cDNA microarray and biological characteristics. A small fraction of lymphoma cells that survived after drug application showed higher expression of stem cell markers (NANOG, and SOX2) and superior ability of self-renewal and sphere formation, compared to untreated control cells (P < 0.05). Gene expression analysis disclosed elevated expression of 41 genes, including FOXO4, in the four lymphoma cell lines that survived drug treatment. Overexpression of FOXO4 was evident in lymphoma cells surviving after phenylbutyrate treatment and refractory patient-derived lymphoma cells. Induction of FOXO4 expression promoted self-renewal whereas its knockdown led to diminished expression of stem cell markers and colony-forming ability of lymphoma cells. Immunohistochemical staining for FOXO4 in tumor tissue of diffuse large B-cell lymphoma revealed nuclear localization and significant association with poor prognosis. In conclusion, lymphoma cells resistant to treatment exhibit stem cell-like properties and enhanced FOXO4 expression. The presence of FOXO4-expressing cells in tumor tissue and their association with poor survival supports a role of FOXO4 in promoting stem cell properties resulting in poor outcomes.

Keywords: stem cell, FOXO4, resistance, B-cell, lymphoma


Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma accounting for ~30–40% of lymphomas in Western and Asian countries [1]. DLBCL is a curable disorder by systemic chemotherapy because lymphoma cells are sensitive to chemotherapy. However, a substantial number of patients still fail to be cured and these treatment failures are mainly associated with drug resistance. Lymphoma cells could acquire drug resistance during they were repeatedly exposed to chemotherapeutic agents. However, a subset of cells with a peculiar characteristics leading to primary refractoriness to chemotherapy might exist at diagnosis even though it has never been treated with chemotherapeutic agents. The concept of cancer stem cells (CSC) has been proposed to explain the existence of a cell population responsible for tumorigenesis as well as primary refractoriness to treatment in patients [24]. The CSC hypothesis postulates that this specific cell population can self-renew and produce daughter cells, continuously leading to treatment failure [5]. Consistently, the association of this cell population with poor prognosis has been suggested in several cancer types, including breast, brain and colon cancer, following the first report on the presence of CSCs in acute myeloid leukemia [610]. Thus, accumulating data support the involvement of CSCs in treatment resistance resulting in tumor relapse and metastasis [11, 12]. At present, limited data on CSCs in DLBCL are available due to a lack of definitive markers, although a few potential markers have been identified in other B-cell lymphomas [13, 14].

In the current study, we developed an in vitro model mimicking a cell population that is primarily refractory to treatment by isolating a cell subset that survived after treatment with the drug at IC90 concentrations (required for 90% inhibition of tumor cell growth). Given that surviving cells after long-term exposure to low-dose drug may represent those cells with acquired rather than intrinsic resistance, we treated cells with high concentrations of drug for a short duration of time. Doxorubicin and phenylbutyrate were used for drug treatment, since doxorubicin is the main chemotherapeutic agent in various regimens for DLBCL and phenylbutyrate is a histone deacetylase inhibitor reported to induce stemness in human induced pluripotent stem cells [15]. Gene expression profiles of the surviving cell population revealed consistent overexpression of forkhead box O 4 (FOXO4), compared with the control group. Although FOXO transcription factors are considered tumor suppressors, contributory roles to cancer progression and maintenance of CSCs in acute and chronic myeloid leukemia have been recently described [1618]. Accordingly, we examined the potential function of FOXO4 in B-cell lymphoma cell populations showing stem cell-like properties, and demonstrated its prognostic value in DLBCL patients.


Generation of B-cell lymphoma cells surviving drug treatment

Seven lymphoma cell lines (BJAB, Raji, Daudi, Toledo, OCI-Ly10, RIVA, and U2932) were treated with the IC90 dose of doxorubicin (300 nM) or phenylbutyrate (8 mM) for 48 h. The majority of cells died after treatment with a few surviving cells, and the proportions of viable cells are specified in Supplementary Table S1. The morphology of lymphoma cells surviving after 48 h incubation with doxorubicin (300 nM) or phenylbutyrate (8 mM) was different from control cells, and their immunophenotype was also different (Figure 1A, 1B). The comparison of immunophenotype using B-cell marker, CD19 showed both groups, surviving cells after treatment with doxorubicin and phenylbutyrate had significantly higher number of CD19-negative cells than control groups. Thus, the proportion of CD45+/CD19− cells which was previously reported as CSC of B-cell lymphoma was significantly higher in surviving cells than control cells (Figure (Figure1B)1B) [13, 14]. Given the nature of drug resistance of surviving cells after IC90 dose of phenylbutyrate (PB cells), drug sensitivity was analyzed. Compared to control cells, BJAB-PB and Raji-PB cells showed higher viability when they were exposed to various concentrations of doxorubicin, prednisolone and rituximab (Figure (Figure1C).1C). Especially, the median inhibitory concentrations (IC50) of doxorubicin were 28.04 and 39.33 nM for BJAB and Raji control cells whereas those for BJAB-PB and Raji-PB cells were over 300 nM (P < 0.05). Thus, phenylbutyrate-treated surviving cells showed resistance to other anti-lymphoma agents.

Figure 1
Generation of B-cell lymphoma cells surviving drug treatment

Stem cell-like properties of B-cell lymphoma cells surviving drug treatment

Because CSC could be related to drug resistance and tumor sphere formation is a surrogate marker of self-renewal of cancer stem cells, we sorted live cells via flow cytometry and plated them in stem cell-selective conditions to observe formation of spheres. As a result, cells surviving after phenylbutyrate treatment generated significantly higher number of tumor spheres compared to control cells (Figure (Figure2A).2A). As phenylbutyrate is known to induce stem cell-like properties in mature tumor cells [15], we further evaluated stem cell-like properties in phenylbutyrate-treated surviving cells. In the soft agar colony formation assays, PB cells showed greater colony formation than control cells (Figure 2B, 2C). In accordance with these findings, the expression of stem cell markers (NANOG and SOX2) was significantly higher in B-cell lymphoma cells survived after phenylbutyrate and doxorubicin treatment than control cells (Figure (Figure2D).2D). This increased expression of stem cell markers was also observed in other B-cell lymphoma cell lines survived after phenylbutyrate and doxorubicin treatment (OCI-Ly10, Riva, and U2932, Supplementary Figure S1). Moreover, BJAB-PB and Raji-PB cells exhibited slower proliferation rates than control cells (Supplementary Figure S2). In consistent with these stem cell-like properties, the BJAB-PB and Raji-PB cells showed significantly higher proportion of aldehyde dehydrogenase (ALDH)-positive cells than control cells (Figure (Figure2E)2E) because ALDH is known as a marker for CSC [19]. The BJAB-PB and Raji-PB cells also showed the enrichment of side-population compared to control cells (Figure (Figure2F),2F), thus, these cell populations represented CSC like previous reports [20, 21]. When we applied another histone deacetylase inhibitor, vorinostat on B-cell lymphoma cells with the same manner, the similar effect of vorinostat on the stemness of lymphoma cells was observed in BJAB and Raji cells (Figure 2G, 2H).

Figure 2
Stem cell-like properties of B-cell lymphoma cells surviving drug treatment

Analysis of gene expression profiles and FOXO4 overexpression

The cDNA microarray analysis was performed to identify the differentially expressed target genes between treatment-surviving and corresponding control cells (Figure (Figure3A).3A). Comparison of the gene expression profiles in four lymphoma cell lines (BJAB, Raji, Toledo, and Daudi) revealed that 41 genes are commonly overexpressed in cells surviving treatment with doxorubicin or phenylbutyrate, compared with untreated control cells (Supplementary Table S2). Among 41 genes, FOXO4 was one of the candidate genes identified because FOXO transcription factors, which are directly inhibited by Akt-dependent phosphorylation, have been implicated in stem cell maintenance of several cell lineages [22]. Increased expression of FOXO4 in phenylbutyrate-treated surviving cells was confirmed in three B-cell lymphoma cell lines (BJAB, Raji and Daudi) and this increased expression of FOXO4 was also found in vorinostat-treated surviving cells (Figure 3B, 3C). FOXO4 expression was also significantly enhanced in surviving cells from other DLBCL cell lines (OCI-Ly10, Riva, and U2932) (Supplementary Figure S3). The increased expression of FOXO4 was found in B-cell lymphoma patient-derived cells. Thus, when three patient-derived primary cells were treated with phenylbutyrate in the same method as cell lines, phenylbutyrate-treated surviving cells showed significant higher expression of FOXO4 than control cells (Figure (Figure3D).3D). Moreover, primary cells obtained from malignant ascites or pleural effusion of refractory B-cell lymphoma patients showed significantly more increased expression of FOXO4 than that of a patient who completely responded to 1st line treatment (Figure (Figure3E3E).

Figure 3
Comparison of gene expression profiles and FOXO4 overexpression

Effect of FOXO4 on stem cell properties of treatment-surviving cells

The expression of FOXO4 target proteins (p21, p27, and SOD2) was increased in BJAB-PB and Raji-PB cells compared with control cells (Figure 4A, 4B). On the other hand, the expression of cell-cycle regulatory proteins (cyclin D1, CDK4, and cyclin A) was reduced in BJAB-PB and Raji-PB cells where FOXO4 expression was increased (Figure 4C, 4D). These results represent FOXO4 could up-regulate the expression of p21, p27, and SOD2 whereas FOXO4 down-regulated the expression of cyclin D1, CDK4, and cyclin A in consistent with a previous report [23]. To ascertain whether FOXO4 affects CSC properties of B cell lymphoma, the amplification of FOXO4 expression increased colony forming ability whereas the knockdown of FOXO4 decreased colony formation in BJAB cell line (Figure (Figure5A).5A). Likewise, BJAB cell with the knockdown of FOXO4 showed a significant decrease of stem cell-associated genes, OCT4, NANOG, and SOCS2 (Figure (Figure5B).5B). Phosphorylated AKT level was decreased in BJAB-PB cells with FOXO4 overexpression whereas siFOXO4-transfected BJAB-PB cells showed the reverse of phosphorylated AKT representing the association of downregulated FOXO4 expression with the phosphorylation of AKT (Figure (Figure5C).5C). The sphere formation was not detectable in parental BJAB cells or clones with low FOXO4 expression, however, the sphere formation was markedly increased in the BJAB clone overexpressing FOXO4 (Figure 5D, 5E).

Figure 4
Effect of FOXO4 on the expression of target proteins in phenylbutyrate treated-surviving cells
Figure 5
The association of FOXO4 with stem cell properties and prognosis of diffuse large B-cell lymphoma

Prognostic value of FOXO4 protein expression in DLBCL patients

In total, 211 patients with DLBCL subjected to at least one cycle of chemotherapy with curative intent were analyzed to evaluate the prognostic value of FOXO4 protein expression. The median age of patients was 59 years (19–86 years). The characteristics of patients at diagnosis are summarized in Table Table1.1. FOXO4-high group was defined as DLBCL cases with more than 70% of positively stained nuclei of tumor cells (Figure (Figure5F).5F). Although the optimal cutoff is not established for nuclear staining of FOXO4, we applied the strict definition for FOXO4-high group because some cases displaying weak nuclear positivity for FOXO4 or cytoplasmic staining in molarity of cells might increase the false positive rate. Thus, all cases other than FOXO4-high group were categorized into FOXO4-low group. Overall, 37 patients (18%, 37/211) were classified as FOXO4-high group. FOXO4-high group was significantly associated with unfavorable characteristics, including advanced stage and increased extranodal involvement (P < 0.05, Table Table1).1). Thus, the high-intermediate/high-risk group of patients according to the International Prognostic Index (IPI) showed more strong association with FOXO4-high group (32%, 15/47) than the low/low-intermediate risk group (13%, 22/164, P = 0.008). Accordingly, the OS and PFS of patients were significantly different according to positivity for FOXO4 (Figure 5G, P < 0.05).

Table 1
Characteristics of patients


Our study used an in vitro model mimicking primary refractory lymphoma cells by isolating the cell fraction that survived after high-dose drug treatment. This subset of lymphoma cells survived after treatment with high-dose doxorubicin and phenylbutyrate exhibited stem cell-like properties compared to the untreated parental cell population including the expression of stem cell markers, colony and sphere forming activity and resistance to chemotherapeutic agents. Because phenylbutyrate was reported to induce pluripotency-associated genes [15], this small population of lymphoma cells might be enriched with cells having stem cell-like properties (so-called CSCs). The presence of CSCs in tumor cells have been demonstrated by the application of ALDH assay and side-population analysis based on characteristics of normal stem cells such as high expression of adenosine triphosphate-binding cassette transporters protecting against cytotoxic agents [1921]. Our study also showed higher proportion of ALDH-positive cells and side-population in this subset of cells survived after the treatment with IC90 dose of phenylbutyrate than control cells (Figure 2E, 2F). Taken together, these findings were consistent with that the small subset of cells could have stem cell-like properties leading to treatment failure in lymphomas.

Given this subset of cells having stem cell-like properties was resistant to chemotherapeutic agents in this study, the comparison of gene expression profiles between treatment-surviving and untreated control cells was performed to find a marker representing the cell populations with drug resistance. Our comparison revealed the increased expression of 41 genes in the four different lymphoma cell lines (BJAB, Raji, Daudi, Toledo, Figure Figure3A).3A). These gene were commonly overexpressed in doxorubicin- and phenylbutyrate-treated surviving cells. Among them, we chose FOXO4 as a candidate gene for indicating the cell fraction with stem cell-like properties because previous studies have suggested the role of FOXO transcription factors in the maintenance of stem cell characteristics [1618]. The increased expression of FOXO4 was also demonstrated in other DLBCL cell lines (OCI-Ly10, Riva, and U2932) when doxorubicin- and phenylbutyrate-treated surviving cells were analyzed (Supplementary Figure S3). Furthermore, primary cells from refractory DLBCL patients showed increased expression of FOXO4 compared to that of patient with complete response (Figure (Figure3E).3E). These results might support the association of FOXO4 expressing cells with CSCs leading to drug resistance. Thus, overexpression of FOXO4 might have a potential role as a predictor of treatment failure in DLBCL.

The FOXO family transcription factors consisting of four members, FOXO1, FOXO3, FOXO4, and FOXO6, are reported to have various roles in the regulation of stress response and oncogenesis [24]. Previous studies reported that FOXOs protect cells under stress conditions (e.g., oxidative stress, serum deprivation or hypoxia) and contribute to cancer progression. Thus, FOXOs were reported to promote invasion and metastasis of colon and breast cancers [2527]. FOXOs also could contribute to the maintenance of leukemia-initiating cells in chronic myeloid leukemia [17, 18, 28]. Likewise, the depletion of FOXOs could induce leukemic cell maturation and cell death in acute myeloid leukemia [16]. In our experiments, expression levels of FOXO4 and its transcriptional targets (p21, p27 and SOD2) were low or undetectable in untreated control cells but highly upregulated in treatment-surviving cells. Additionally, FOXO4 expression led to enhanced transcription of stem cell factors and self-renewal activity of lymphoma cells whereas its knockdown had opposite effects. The major mechanism of FOXO regulation is associated with phosphorylation by Akt and other kinases [29]. Phosphorylation of FOXO factors lead to their nuclear export and abrogation of transcriptional activity. Accordingly, we analyzed the association of FOXO4-positive cells with treatment failure using an archived tumor tissue array of DLBCL patients. In our study, the survival outcome of FOXO4-high group was significantly worse than that of FOXO4-low group (Figure (Figure5G5G).

In conclusion, a small subset of lymphoma cells surviving treatment with doxorubicin or phenylbutyrate showed stem cell-like properties including the expression of stem cell markers, increased colony and sphere formation and resistance to chemotherapeutic agents. The overexpression of FOXO4 was found in these surviving cells, and DLBCL patients with FOXO4-positive tumor cells had poor prognosis. Thus, our results might suggest a role of FOXO4 as an indicator for the presence of cell population enriched with CSCs leading to drug resistance and treatment failure.


Cell lines and cultures

The following human B-cell lymphoma cell lines were used for culture: three Burkitt's lymphoma cell lines (BJAB, Raji, Daudi), one germinal center type DLBCL line (Toledo), and three activated B-cell type DLBCL cell lines (Riva, U2932, and OCI-Ly10). Toledo, Daudi and Raji were purchased from ATCC (Rockville, MD), and Riva and U2932 from DSMZ (Braunschweig, Germany). BJAB cells were obtained from Dr. W.S. Kim (Sungkyunkwan University) and OCI-Ly10 from Dr. Y.K. Jeon (Seoul National University Hospital). Patient-derived primary cells were acquired from malignant pleural effusion or ascites of patients with DLBCL. Seven patients had refractory disease whereas one patient achieved complete response to the 1st line chemotherapy. Cells were cultured in RPMI 1640 supplemented with heat-inactivated 10% fetal bovine serum, penicillin and streptomycin (Gibco BRL, Grand Island, NY), except OCI-Ly10, which was cultured in Iscove's modified Dulbecco's medium.

Flow cytometry

Cells were suspended at a concentration of 5 × 105 cells in Dulbecco's Phosphate Buffered Saline (DPBS) containing 2% fetal bovine serum (FBS) and incubated with CD45 and CD19 or isotype control (BD Bioscience) for 1 h at 4°C. After washing with PBS, cells were analyzed via flow cytometry (FACSverse, BD Biosciences, San Jose, CA, USA).

May-Grünwald-Giemsa staining

Cells (2 × 104 cells) were fixed in methanol for 2–3 min and stained with May-Grünwald solution for 15 min, followed by Giemsa solution for 10 min. After washing with H2O, cell morphology was examined under a microscope.

Gene expression analysis following drug treatment

The IC90 concentration of doxorubicin and phenylbutyrate (Enzo life science, INC, Farmingdale, NY, USA) was determined as the dose that induced 90% tumor cell death. For drug treatment, four cell lines (BJAB, Raji, Daudi and Toledo) were seeded at a density of 5 × 106 cells per 150 mm dish and incubated with 300 nM doxorubicin or 8 mM phenylbutyrate for 48 h. For the negative control, the same cell lines were incubated with DPBS for 48 h. Cell viability was determined by cell counting using a hemocytometer (Hausser Scientific, Horsham, PA, USA) after staining with 0.4% Trypan blue solution (Sigma-Aldrich, Inc., St Louis, MO, USA). Viable cells were sorted using a BD FACSAria™ III cell sorter, and total RNA extracted with TRIzol (Invitrogen Life Technologies, Carlsbad, CA) and amplified using the TargetAmp-Nano Labeling Kit for Illumina Expression BeadChip (EPICENTRE, Madison). Labeled RNA samples were prepared according to the manufacturer's instructions (Illumina, Inc., San Diego), and array signals detected with Amersham fluorolink streptavidin-Cy3 (GE Healthcare Biosciences, Little Chalfont, UK). Raw data were extracted using the software provided by the manufacturer (Illumina GenomeStudio v2011. 1 (Gene Expression Module v1.9.0)). Array probes with detection p-values ≥ 0.05 (similar to signal-to-noise) in over 50% samples were filtered out. We applied a filtering criterion for data analysis. Thus, a higher signal value was required to obtain a detection p-value < 0.05. The selected gene signal value was transformed by the logarithm and normalized with the quantile method. The statistical significance of expression data was determined based on fold change. Gene Enrichment and Functional Annotation analyses were performed with DAVID ( All data analyses and visualization of differentially expressed genes were conducted using R 2.15.1 (

Cell survival and colony formation assays

Cells were seeded at a density of 5 × 104 per well in 24-well plates and incubated with 0–1 μM doxorubicin, 0–3 μM prednisolone for 24 h and 0–100 ug/ml rituximab for 72 h. After this period, cells were stained with 0.4% trypan blue solution (Sigma-Aldrich, Inc) and counted using a hemocytometer (Hausser Scientific, Horsham, PA). Data were expressed as percentage cell proliferation, taking the number of living cells incubated with DPBS as 100% reference. For colony formation, cells were seeded in triplicate at a density of 5 × 103 cells per well in six-well plates. The base agar was 0.3% agar containing RPMI 1640 with 10% FBS while the top agar was 0.6% agar in the same culture medium. A 2 ml aliquot of medium was added, and the plates incubated at 37°C. Colonies were counted after 2 weeks.

Side population analysis

The cells were suspended at 1 × 106 cells of RPMI 1640 medium containing 2% FBS and 10 mM HEPES buffer and incubated with Hoechst 33342 dye (Sigma-Aldrich, Inc) at a final concentration of 5 μg/mL at 37°C for 60 minutes in the dark, either alone or in the presence of 100 μM verapamil (Sigma-Aldrich). After washing with PBS, cells were analyzed by flow cytometry (FACSAria SORP, BD biosciences). Hoechst 33342 dye was excited with a UV laser at 355 nm, and fluorescence emission from Hoechst blue was collected with a 450/50 band pass (BP) filter and Hoechst red was collected with a 670 LP filter.

Aldehyde dehydrogenase (ALDH) assay

ALDH activity was measured using the ALDEFLUOR kit (Stemcell Technologies, Vancouver, BC, Canada) according to the manufacturer's protocol. The cells (1.0 × 106 cells) were incubated with ALDEFLUOR assay buffer for 60 min at 37°C, either alone or in the presence of the specific ALDH1 enzyme inhibitor diethylaminobenzaldehyde (DEAB), which was a negative control. After washing with PBS, cells were analyzed by flow cytometry (FACSverse, BD Biosciences, San Jose, CA, USA).

Reverse transcriptase (RT)–PCR

Total RNA was extracted using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's protocol. For reverse transcription, 2 μg RNA was converted to cDNA using an Omniscript RT kit (Qiagen, Valencia, CA, USA). The generated cDNA was amplified using specific primers, with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal normalization control. Each PCR cycle consisted of denaturation at 94°C for 30 sec, primer annealing at 58°C for 30 sec, and extension at 72°C for 30 sec. Sample was amplified for 35 cycles, and an additional extension step carried out at 72°C for 5 min. The specific primer sequences were as follows: FOXO4 forward, 5′- TGG GCT CAA TCT CAC CTC TTC C -3′ and FOXO4 reverse, 5′- AGA AGC ACC CTT CTC CTG CTG A -3′; NANOG forward, 5′-AAA GAA TCT TCA CCT ATG CC-3′ and NANOG reverse, 5′-GAA GGA AGA GGA GAG ACA GT-3′; OCT4 forward, 5′-CGA CCA TCT GCC GCT TTG AG-3′ and OCT4 reverse, 5′-CCC CCT GTC CCC CAT TCC TA-3′; SOX2 forward, 5′- CCT CCG GGA CAT GAT CAG -3′ and SOX2 reverse, 5′- TTC TCC CCC CTC CAG TTC -3′; GAPDH forward, 5′-ACA GTC AGC CGC ATC TTC TT -3′ AND GAPDH REVERSE, 5′- GAC AAG CTT CCC GTT CTC AG -3′.

Quantitative real-time PCR

Real-time quantitative polymerase chain reaction (qPCR) primers for FOXO4, Nanog, OCT4, SOX2 and β-actin were purchased from Applied Biosystems (TaqMan Gene Expression Assays, Austin, TX), and reactions performed according to the manufacturer's protocol. Reactions were carried out in an ABI7900HT system, and the results expressed as fold change calculated with the ΔΔCt method relative to the control sample. β-Actin was used as the internal normalization control.

Plasmids, siRNAs and transfection

FOXO4-Flag overexpression constructs were generated as follows: FOXO4 cDNA was obtained from Addgene (plasmid 17549) and subcloned into a pCMV tag4C vector to generate pCMV tag4C FOXO4-Flag. BJAB was transfected with pCMV tag4C FOXO4-Flag or empty vector using the Amaxa Nucleofector™ kit T and the corresponding Amaxa Nucleofector™ System (Amaxa, Gaithersburg, MD). Stable cell lines overexpressing FOXO4 were selected with changes of fresh medium containing G418 (500 μg/ml) for 4 weeks. FOXO4-targeting and control siRNA were purchased from Dharmacon (Thermo Scientific, Waltham, MA).

Western blot

Whole cell lysates were prepared using ice-cold RIPA buffer (0.5% sodium deoxycholate, 1% Nonidet P-40, 150 mM NaCl, 50 mM Tris [pH 7.5], 0.1% sodium dodecyl sulfate [SDS] and 1 mM phenylmethylsulfonyl fluoride [PMSF]) and cleared by microcentrifugation (14 000 rpm for 30 min at 4°C). The protein concentration in each sample was estimated with the BCA Assay. In total, 30–40 μg protein sample was electrophoresed on a 12% SDS polyacrylamide gel (SDS-PAGE) and electroblotted onto nitrocellulose membranes. After 1 h of incubation in blocking solution (5% non-fat milk), membranes were exposed overnight at 4°C to primary antibodies, included those against FOXO4, pAKT, AKT (Cell Signaling, Danvers, MA), p27 (BD Pharmingen, San Diego, CA), p21, cyclin D1, cyclin A, CDK4 and β-actin (Santa Cruz Biotechnology, Santa. Cruz, CA, USA). The blot was washed with TBST buffer (50 mM Tris [pH 7.5], 150 mM NaCl. 0.05% Tween 20) and further exposed to horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. Proteins were visualized using enhanced chemiluminescence (ECL) reagent (Amersham Pharmacia Biotech, Arlington Heights, IL).


FOXO4 expression was analyzed in archived tissue arrays of DLBCL patients from Samsung Medical Center pathologically diagnosed with DLBCL and treated using systemic chemotherapy with curative content. Clinical data, including disease and survival status, were updated in December 2015, and written informed consent from patients exempted by the Samsung Medical Center Institutional Review Board due to the retrospective nature of the study. Immunohistochemical analysis of FOXO4 was performed on formalin-fixed, paraffin-embedded, 4 μm thick tissue sections. Tissue sections were deparaffinized three times in xylene for a total of 15 min, and antigen retrieval performed for 20 min with ER1 buffer (pH 6.0) in 97°C. After endogenous peroxidase blocking for 5 min, tissues were incubated with primary polyclonal antibody against FOXO4 (1:1000; GTX50500; GeneTex, Irvine, CA, USA) for 15 min using a BOND-MAX autoimmunostainer (Leica Biosystems, Melbourne, Australia) for 15 min. The secondary antibody reaction was performed using a BOND-MAX autoimmunostainer (Leica Biosystems, Melbourne, Australia) with the BOND Polymer Refine Detection system (DS9800; Vision BioSystems, Melbourne, Australia) for 10 min. Positivity for FOXO4 was determined by comparing with the normal positive control from the tonsillar germinal center. In every staining set, a negative control was included in which primary antibodies and probes were omitted. Stained slides were reviewed, and the extent of tissue expression determined by pathologists (M.H. and Y.H.K).

Statistical analysis

Categorical variables were analyzed with Fisher's exact test. Progression-free survival (PFS) was calculated from the date of diagnosis to the first day of progression, relapse or death from any cause. Overall survival (OS) was calculated from the date of diagnosis to death. Survival curves were estimated with the Kaplan–Meier method and compared using the log-rank test. P values < 0.05 were considered significant, and two-sided tests used in all calculations. Statistical analyses were performed using the IBM PASW version 18.0 package (SPSS Inc., Chicago, IL, USA).



This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2014R1A2A1A11049853).



The authors have no conflicts of interest to report.


1. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol. 2005;23:6387–6393. [PubMed]
2. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012;12:133–143. [PubMed]
3. Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology. 2014;28:1101–1107. 1110. [PubMed]
4. Medema JP. Cancer stem cells: the challenges ahead. Nat Cell Biol. 2013;15:338–344. [PubMed]
5. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111. [PubMed]
6. Warner JK, Wang JC, Hope KJ, Jin L, Dick JE. Concepts of human leukemic development. Oncogene. 2004;23:7164–7177. [PubMed]
7. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401. [PubMed]
8. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–10951. [PubMed]
9. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–115. [PubMed]
10. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313–323. [PubMed]
11. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–284. [PubMed]
12. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst. 2006;98:1755–1757. [PubMed]
13. Jung HJ, Chen Z, McCarty N. Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma. Leuk Lymphoma. 2011;52:1066–1079. [PubMed]
14. Kim SM, Lee ST, Ryu KJ, Kim HJ, Kim SH, Ko YH, Kim WS, Kim SJ. A subset of CD45+/CD19− cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma. Leuk Lymphoma. 2015;56:3052–3057. [PubMed]
15. Mali P, Chou BK, Yen J, Ye Z, Zou J, Dowey S, Brodsky RA, Ohm JE, Yu W, Baylin SB, Yusa K, Bradley A, Meyers DJ, et al. Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells. 2010;28:713–720. [PMC free article] [PubMed]
16. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 2011;146:697–708. [PMC free article] [PubMed]
17. Pellicano F, Scott MT, Helgason GV, Hopcroft LE, Allan EK, Aspinall-O’Dea M, Copland M, Pierce A, Huntly BJ, Whetton AD, Holyoake TL. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells. 2014;32:2324–2337. [PMC free article] [PubMed]
18. Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, Nakao S, Motoyama N, Hirao A. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463:676–680. [PubMed]
19. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle. 2011;10:1378–1384. [PubMed]
20. Lee MR, Ju HJ, Kim BS, Ko YH, Kim WS, Kim SJ. Isolation of side population cells in B-cell non-Hodgkin's lymphomas. Acta Haematol. 2013;129:10–17. [PubMed]
21. Moti N, Malcolm T, Hamoudi R, Mian S, Garland G, Hook CE, Burke GA, Wasik MA, Merkel O, Kenner L, Laurenti E, Dick JE, Turner SD. Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin. Oncogene. 2015;34:1843–1852. [PubMed]
22. Saoncella S, Tassone B, Deklic E, Avolio F, Jon C, Tornillo G, E De Luca, E Di Iorio, Piva R, Cabodi S, Turco E, Pandolfi PP, Calautti E. Nuclear Akt2 opposes glimbal keratinocyte stem cell self-renewal by repressing a FOXO-mTORC1 signaling pathway. Stem Cells. 2014;32:754–769. [PubMed]
23. Ho KK, Myatt SS, Lam EW. Many forks in the path: cycling with FoxO. Oncogene. 2008;27:2300–2311. [PubMed]
24. Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis. Oncogene. 2008;27:2312–2319. [PMC free article] [PubMed]
25. Sisci D, Maris P, Cesario MG, Anselmo W, Coroniti R, Trombino GE, Romeo F, Ferraro A, Lanzino M, Aquila S, Maggiolini M, Mauro L, Morelli C, et al. The estrogen receptor alpha is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness. Cell Cycle. 2013;12:3405–3420. [PMC free article] [PubMed]
26. Storz P, Doppler H, Copland JA, Simpson KJ, Toker A. FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases. Mol Cell Biol. 2009;29:4906–4917. [PMC free article] [PubMed]
27. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S, Fernandez Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramon y Cajal S, Schwartz S, et al. beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med. 2012;18:892–901. [PubMed]
28. Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Muller MC, Hofmann WK, Hochhaus A, Ye BH, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011;208:2163–2174. [PMC free article] [PubMed]
29. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857–868. [PubMed]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC